Compare this test’s laboratory options
CVD & Diabetes Prevention Comprehensive
Boston Heart Diagnostics1 test optionFrom $802.20
CVD & Diabetes Prevention Comprehensive
Boston Heart DiagnosticsCatalog information reviewed: August 24, 2026 by the Sunridge Medical clinical team.
What this laboratory test evaluates
This test is one of Boston Heart's 2 curated profiles for prevention of cardiovascular disease (CVD) and type-2 diabetes, or complication of these conditions. These profiles are excellent for monitoring patients with obesity, insulin resistance, metabolic syndrome, pre-diabetes, or diabetes. Such patients are at a 2 to 4 times higher risk for CVD than patients without these conditions.
Cardiovascular disease, type 2 diabetes, metabolic syndrome, and obesity are widespread and very common among patients. These lifestyle diseases are largely preventable, treatable, and reversible. The right combination of blood tests can unmask and monitor risk for serious health problems including premature death and dramatically reduced quality of life.
Advanced Lipid TestingRoutine lipid testing is insufficient to identify and monitor patients at risk adequately. Small Dense LDL-C, apoB, Lp(a), cholesterol production and absorption, fatty acids and HDL metabolism are all important for uncovering and treating hidden risk.
MetabolicsObesity, insulin resistance, metabolic syndrome, prediabetes, and type-2 diabetes are widespread epidemics. Cardiovascular disease is the leading cause of death in patients with these conditions. Monitoring glucose and HbA1c are crucially important for prevention, early identification, treatment, and reversal of type-2 diabetes and cardiovascular risk. These profiles go a step further by evaluating insulin levels, calculated insulin resistance & sensitivity, calculated beta cell activity, and the Boston Heart Beta Cell Function and Risk Index™. Together these tests can evaluate the potential role of specific therapies to address insulin resistance and/or beta cell dysfunction.
InflammationAtherosclerosis is an inflammatory disease which affects all patients with diabetes. After ruling out other causes of inflammation, C-reactive protein (CRP) is a strong independent predictor of CVD. Lowering CRP with statins in patients with normal LDL-C reduces CVD events. LpPLA2 measures inflammation specific to oxidized cholesterol plaque in the artery wall and reflects overall atherosclerotic burden. Oxidized phospholipid on apoB particles (OxPL-apoB) is highly pro-inflammatory and levels can be used to reclassify patients into higher or lower risk categories allowing for better personalized care. Inflammation can be reduced by treating the underlying causes including abnormal lipids, glucose, blood pressure, smoking, processed food and low physical activity. Furthermore, randomized trials indicate that patients with diabetes who have increased oxidation due to the haptoglobin variant Hp2/2 reduce CVD risk with natural vitamin E supplementation.
ChemistriesElectrolytes, kidney function, liver function and other measures of normal metabolic activity are valuable tools for health assessment and patient management. Homocysteine, uric acid, and vitamin D are each associated with CVD risk and can be improved with healthy lifestyle choices. When deficiencies are detected, it is important to understand the underlying cause to determine whether supplementation is appropriate to normalize levels.
Additional test information
Inclusive of the CVD & Diabetes Prevention test, this panel adds a deeper evaluation of the patient's metabolic markers along with others to identify areas in the diet that can be improved. It helps to identify the causes and where to treat to make the biggest improvements in cardiometabolic health.
Collection and processing
- Sample type: Plasma, Serum, Whole blood
- Fasting: Yes
- Estimated laboratory processing: Results should arrive 14 business days after the lab receives samples.
How Sunridge uses laboratory information
Sunridge considers the medical question, symptoms, history, medications, prior results, and whether the finding could change care before recommending testing. A laboratory result is not interpreted in isolation and does not establish a diagnosis by itself.
Before requesting this test
Availability, collection requirements, eligibility, and processing estimates can change. Sunridge reviews each request and, when appropriate, creates the order through Fullscript. Follow the current instructions supplied with the approved order.
Common questions about this laboratory test
- What sample does this test require?
- The listed sample type is Plasma, Serum, Whole blood. Confirm current collection instructions in the approved order.
- Does this test require fasting?
- The current catalog record lists fasting as: Yes. Follow the instructions supplied with the approved order.
- How long does laboratory processing usually take?
- Results should arrive 14 business days after the lab receives samples.. Timing can change after collection or if a laboratory requires additional review.
About this test
This test is one of Boston Heart's 2 curated profiles for prevention of cardiovascular disease (CVD) and type-2 diabetes, or complication of these conditions. These profiles are excellent for monitoring patients with obesity, insulin resistance, metabolic syndrome, pre-diabetes, or diabetes. Such patients are at a 2 to 4 times higher risk for CVD than patients without these conditions.
Cardiovascular disease, type 2 diabetes, metabolic syndrome, and obesity are widespread and very common among patients. These lifestyle diseases are largely preventable, treatable, and reversible. The right combination of blood tests can unmask and monitor risk for serious health problems including premature death and dramatically reduced quality of life.
Advanced Lipid TestingRoutine lipid testing is insufficient to identify and monitor patients at risk adequately. Small Dense LDL-C, apoB, Lp(a), cholesterol production and absorption, fatty acids and HDL metabolism are all important for uncovering and treating hidden risk.
MetabolicsObesity, insulin resistance, metabolic syndrome, prediabetes, and type-2 diabetes are widespread epidemics. Cardiovascular disease is the leading cause of death in patients with these conditions. Monitoring glucose and HbA1c are crucially important for prevention, early identification, treatment, and reversal of type-2 diabetes and cardiovascular risk. These profiles go a step further by evaluating insulin levels, calculated insulin resistance & sensitivity, calculated beta cell activity, and the Boston Heart Beta Cell Function and Risk Index™. Together these tests can evaluate the potential role of specific therapies to address insulin resistance and/or beta cell dysfunction.
InflammationAtherosclerosis is an inflammatory disease which affects all patients with diabetes. After ruling out other causes of inflammation, C-reactive protein (CRP) is a strong independent predictor of CVD. Lowering CRP with statins in patients with normal LDL-C reduces CVD events. LpPLA2 measures inflammation specific to oxidized cholesterol plaque in the artery wall and reflects overall atherosclerotic burden. Oxidized phospholipid on apoB particles (OxPL-apoB) is highly pro-inflammatory and levels can be used to reclassify patients into higher or lower risk categories allowing for better personalized care. Inflammation can be reduced by treating the underlying causes including abnormal lipids, glucose, blood pressure, smoking, processed food and low physical activity. Furthermore, randomized trials indicate that patients with diabetes who have increased oxidation due to the haptoglobin variant Hp2/2 reduce CVD risk with natural vitamin E supplementation.
ChemistriesElectrolytes, kidney function, liver function and other measures of normal metabolic activity are valuable tools for health assessment and patient management. Homocysteine, uric acid, and vitamin D are each associated with CVD risk and can be improved with healthy lifestyle choices. When deficiencies are detected, it is important to understand the underlying cause to determine whether supplementation is appropriate to normalize levels.
Additional details
Inclusive of the CVD & Diabetes Prevention test, this panel adds a deeper evaluation of the patient's metabolic markers along with others to identify areas in the diet that can be improved. It helps to identify the causes and where to treat to make the biggest improvements in cardiometabolic health.
Highlighted health areas
- Cardiovascular
- Metabolic function
Biomarkers and report focus
The exact analytes and report format can change. Confirm the current contents in the Fullscript order before payment.
- Vitamin D, 25-OH, Total
- Creatinine
- hsCRP
- Lp-PLA2
- Apolipoprotein B
- Homocysteine
- Total Bilirubin
- Estimated Glomerular Filtration Rate
- Uric Acid
- Hemoglobin A1c
- Triglycerides
- Total Cholesterol
- Alkaline Phosphatase (ALP)
- Albumin
- Calcium
- Blood Urea Nitrogen
- Carbon Dioxide
- Chloride
- Potassium
- Sodium
- HDL Cholesterol
- Direct LDL
- Aspartate Aminotransferase (AST)
- Alanine Aminotransferase (ALT)
- Arachidonic Acid/EPA Ratio
- Omega-3 Index
- Glucose, Fasting
- Protein, Total
- sdLDL
- Adiponectin, Blood
View all 60 listed biomarkers
- Apolipoprotein A-1, Blood
- Beta sitosterol
- Campesterol
- Cholestanol
- Desmosterol
- Eicosapentaenoic Acid/Arachidonic Acid Ratio
- Insulin, Fasting
- HOMA-IR
- Lathosterol
- Lipoprotein (a), Blood
- alpha-1 HDL
- alpha-2 HDL
- alpha-3 HDL
- alpha-4 HDL
- Glycated Serum Protein
- HOMA-B
- HOMA-S
- Oxidized Phospholipids on apoB
- Pre-Beta-1 HDL
- Trans Fatty Acid Index
- Unsaturated / Saturated Ratio
- Saturated Fatty Acid Index
- Monounsaturated Fatty Acid Index
- Omega-6 Index
- Omega-3/Omega-6 Ratio
- Alpha Linolenic C18:3w3
- Arachidonic C20:4w6
- Docosahexaenoic C22:6w3
- Eicosapentaenoic C20:5w3
- Linoleic, C18:2w6